EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.
EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.
2018 Korea CPHI, C30
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
1.
Ivabradine hydrochloride, CAS#148849-67-6, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 36KG in stock, pls check:
Name: Ivabradine hydrochloride
CAS#: 148849-67-6
Formula: C27H37ClN2O5
Exact Mass:
Molecular Weight: 505.05
Elemental Analysis: C, 64.21; H, 7.38; Cl, 7.02; N, 5.55; O, 15.84
Exact Mass:
Molecular Weight: 505.05
Elemental Analysis: C, 64.21; H, 7.38; Cl, 7.02; N, 5.55; O, 15.84
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
2.
Ivabradine hydrochloride Intermediates:
1. Ivabradine hydrochloride Intermediate:3,4-dimethoxy-N-methyl-bicyclo[4.2.0]octa-1,3,5-triene-7-methanamine hydrochloride,
Cas#866783-13-3,
We have more than 46kg in stock, assay 99% in GMP plant, C-GMP standard,
now COA, NMR, HPLC, MS is ok.
2. Ivabradine hydrochloride Intermediate:3-(3-chloropropyl)-1,3-dihydro-7,8-dimethoxy-2H-3-Benzazepin-2-one
Cas#85175-59-3,
We have more than 56kg in stock, assay 99% in GMP plant, C-GMP standard,
now COA, NMR, HPLC, MS is ok.
1. Ivabradine hydrochloride Intermediate:3,4-dimethoxy-N-methyl-bicyclo[4.2.0]octa-1,3,5-triene-7-methanamine hydrochloride,
Cas#866783-13-3,
We have more than 46kg in stock, assay 99% in GMP plant, C-GMP standard,
now COA, NMR, HPLC, MS is ok.
2. Ivabradine hydrochloride Intermediate:3-(3-chloropropyl)-1,3-dihydro-7,8-dimethoxy-2H-3-Benzazepin-2-one
Cas#85175-59-3,
We have more than 56kg in stock, assay 99% in GMP plant, C-GMP standard,
now COA, NMR, HPLC, MS is ok.
REFERENCE
1: Dyakov IN, Gleser MG. [Clinical and Economic Efficacy of Ivabradine in Patients Suffered Myocardial Infarction]. Kardiologiia. 2015;55(3):49-55. Russian. PubMed PMID: 26320290.
2: Hancox JC, Melgari D, Dempsey CE, Brack KE, Mitcheson J, Ng GA. hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes. Ther Adv Drug Saf. 2015 Aug;6(4):177-9. doi: 10.1177/2042098615595546. PubMed PMID: 26301071; PubMed Central PMCID: PMC4530352.
3: Lees-Miller JP, Guo J, Wang Y, Perissinotti LL, Noskov SY, Duff HJ. In response to Melgari et al. "hERG potassium channel inhibition by ivabradine requires channel gating". J Mol Cell Cardiol. 2015 Aug 20;87:192-193. doi: 10.1016/j.yjmcc.2015.08.003. [Epub ahead of print] PubMed PMID: 26299838.
4: Tagliamonte E, Cirillo T, Rigo F, Astarita C, Coppola A, Romano C, Capuano N. Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate. Adv Ther. 2015 Aug 21. [Epub ahead of print] PubMed PMID: 26293212.
5: Melgari D, Brack KE, Zhang Y, El Harchi A, Mitcheson JS, Dempsey CE, Ng GA, Hancox JC. hERG potassium channel inhibition by ivabradine requires channel gating. J Mol Cell Cardiol. 2015 Aug 11;87:126-128. doi: 10.1016/j.yjmcc.2015.08.002. [Epub ahead of print] PubMed PMID: 26275355.
6: Choi HY, Bae KS, Cho SH, Ghim JL, Choe S, Jung JA, Lim HS. Population plasma and urine pharmacokinetics of ivabradine and its active metabolite S18982 in Korean healthy volunteers. J Clin Pharmacol. 2015 Aug 11. doi: 10.1002/jcph.614. [Epub ahead of print] PubMed PMID: 26265098.
7: Beltrame JF. Ivabradine and the SIGNIFY conundrum. Eur Heart J. 2015 Aug 11. pii: ehv368. [Epub ahead of print] PubMed PMID: 26264551.
8: Reil JC, Bohm M. Can ivabradine still be used in clinical practice after the 'SIGNIFY' trial? Eur Heart J. 2015 Jun 7;36(22):1353-4. PubMed PMID: 26251857.
9: Barzilai M, Jacob G. The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome Patients. Rambam Maimonides Med J. 2015 Jul 30;6(3). doi: 10.5041/RMMJ.10213. PubMed PMID: 26241226; PubMed Central PMCID: PMC4524401.
10: Gómez Casal V, Lage Cendon L, Lago Preciado G, Vara Adrio S. Ivabradine poisoning with suicide intention. Med Intensiva. 2015 Jul 21. pii: S0210-5691(15)00107-2. doi: 10.1016/j.medin.2015.04.008. [Epub ahead of print] English, Spanish. PubMed PMID: 26208765.
11: Chen XP, Zheng HT, Cai WW, Li MK, Zhang JW, Hu J. The Effect of Silibinin on the Pharmacokinetics of Ivabradine and N-Desmethylivabradine in Rats. Pharmacology. 2015;96(3-4):107-11. doi: 10.1159/000435890. Epub 2015 Jul 18. PubMed PMID: 26202095.
12: Glezer MG; LINCOR Program. [Effect of Treatment With Ivabradine on Quality of Life of Patients With Ischemic Heart Disease: Results of the LINCOR Program]. Kardiologiia. 2015;55(2):4-9. Russian. PubMed PMID: 26164981.
13: Liu DQ, Yu JH, Zhang YF, Zhong DF, He L, Chen XY. [Effects of stable isotope labeled internal standard on determination of ivabradine and N-demethylivabradine in human plasma]. Yao Xue Xue Bao. 2015 Mar;50(3):348-54. Chinese. PubMed PMID: 26118116.
14: Kadro W. 2D.09: THE EFFECT OF IVABRADINE ON SILENT AMBULATORY MYOCARDIAL ISCHEMIA. J Hypertens. 2015 Jun;33 Suppl 1:e30. doi: 10.1097/01.hjh.0000467430.64806.58. PubMed PMID: 26102788.
15: Dias da Silva VJ, Tobaldini E, Rocchetti M, Wu MA, Malfatto G, Montano N, Zaza A. Modulation of sympathetic activity and heart rate variability by ivabradine. Cardiovasc Res. 2015 Jun 22. pii: cvv180. [Epub ahead of print] PubMed PMID: 26101263.
16: Cademartiri F, Garot J, Tendera M, Zamorano JL. Intravenous ivabradine for control of heart rate during coronary CT angiography: A randomized, double-blind, placebo-controlled trial. J Cardiovasc Comput Tomogr. 2015 Jul-Aug;9(4):286-94. doi: 10.1016/j.jcct.2015.04.005. Epub 2015 Apr 27. PubMed PMID: 26088378.
17: Kleinbongard P, Gedik N, Witting P, Freedman B, Klöcker N, Heusch G. Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br J Pharmacol. 2015 Sep;172(17):4380-90. doi: 10.1111/bph.13220. Epub 2015 Jul 21. PubMed PMID: 26076181.
18: McMurray JJ. It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD? Eur Heart J. 2015 Aug 14;36(31):2047-2049. Epub 2015 May 20. Review. PubMed PMID: 25994745.
19: Ivabradine (Corlanor) for heart failure. Med Lett Drugs Ther. 2015 May 25;57(1469):75-6. PubMed PMID: 25989196.
20: Traynor K. Ivabradine approved for stable chronic heart failure. Am J Health Syst Pharm. 2015 Jun 1;72(11):896. doi: 10.2146/news150037. PubMed PMID: 25987676.
